Sinopharm Group Co., Ltd is one of China’s largest state-owned integrated healthcare companies, primarily focused on the research, development, production and distribution of a broad range of pharmaceutical and healthcare products. Established in 1998 through the reorganization of assets under China National Pharmaceutical Group (Sinopharm), the company has grown to encompass multiple business segments, including prescription medicines, over-the-counter drugs, vaccines and medical devices. Sinopharm Group is listed on the Hong Kong Stock Exchange and trades in the United States through its OTCMKTS ticker SHTDF.
The company’s product portfolio spans chemically synthesized drugs, biologics and traditional Chinese medicine formulations, supported by an extensive nationwide manufacturing and quality-control network. Sinopharm Group is also a major supplier of vaccines in China, delivering both routine immunizations and emergency-use vaccines, including its COVID-19 portfolio. In addition to pharmaceutical R&D and production, the company operates a network of retail pharmacies and provides logistics, cold-chain distribution and hospital procurement services, enabling it to serve hospitals, clinics and end-users across the healthcare value chain.
Headquartered in Beijing, Sinopharm Group has built a presence throughout mainland China via regional subsidiaries and distribution centers, and it has progressively expanded its international footprint through export partnerships and joint ventures in Asia, Africa and Latin America. Leveraging its state-backed heritage and broad operational scope, the company continues to focus on advancing innovation, strengthening its supply capabilities and collaborating with global health organizations to address public health needs at home and abroad.
AI Generated. May Contain Errors.
